GlassScriptPhysician profile
Caroline Morgan Ready
NPI 1255076659
$4,924.85
in general payments reported to CMS, 2019-2025
26 companies · $3,299 in 2025
The $3,299 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.20 · 2023: $894 · 2024: $708 · 2025: $3,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,901.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $849.44 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $617.54 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Gilead Sciences, INC. | $442.68 | 2022-2024 | Descovy |
| Vanda Pharmaceuticals INC. | $433.29 | 2025 | Fanapt, Hetlioz |
| Myriad Women'S Health, INC. | $430.65 | 2023 | Myrisk |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $371.43 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $274.13 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $258.75 | 2025 | Uzedy, Austedo Xr |
| Astellas Pharma US INC | $239.65 | 2023-2024 | Veozah, Myrbetriq |
| Viiv Healthcare Company | $152.24 | 2024 | Apretude |
| Alkermes, INC. | $142.46 | 2025 | Aristada, Lybalvi, Vivitrol |
| Neos Therapeutics, LP | $107.50 | 2023-2024 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $82.73 | 2025 | Cobenfy |
| Lilly USA, LLC | $56.45 | 2023-2024 | Jardiance, Lyumjev |
| Tris Pharma INC | $56.37 | 2025 | Dyanavel Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $50.00 | 2024 | Reltone 200 Mg, Reltone 400 Mg |
| Neurocrine Biosciences, INC. | $46.35 | 2025 | |
| Corium, LLC | $46.12 | 2025 | Azstarys |
| Noven Therapeutics, LLC | $44.91 | 2025 | Xelstrym |
| Novo Nordisk INC | $43.95 | 2024 | Ozempic, Rybelsus |
| Tms Neurohealth Centers INC. | $41.47 | 2025 | Tms Neurohealth Centers INC. |
| Collegium Pharmaceutical, INC. | $34.46 | 2025 | Jornay Pm |
| Regeneron Healthcare Solutions, INC. | $30.61 | 2024 | Dupixent |
| Philips North America LLC | $28.37 | 2024 | (Ck7) Extended Holter |
| Pfizer INC. | $23.48 | 2023 | |
| Xeris Pharmaceuticals, INC. | $19.82 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Ready listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.